Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206877 · ClinicalTrials.gov registry record · Phase 1
Topical Insulin for Glaucoma
A Phase 1 study of Glaucoma, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05206877 is a Phase 1 study of Glaucoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 52 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05206877, a Phase 1 study of Glaucoma, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Conditions Studied
Interventions
- DRUG Insulin, 4 units
- DRUG Insulin, 20 units
- DRUG insulin, 4 units twice daily
- DRUG insulin, 20 units twice daily
- DRUG insulin, 4 units three times daily
Study Locations (1)
California
- Byers Eye Institute at Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05206877
The ClinicalTrials.gov registry entry for NCT05206877 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 5 interventions - of which Insulin, 4 units is the first listed.
NCT05206877 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05206877 about?
NCT05206877 is a clinical study titled "Topical Insulin for Glaucoma". The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
What is the current status of trial NCT05206877?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05206877 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT05206877?
The interventions under investigation include: Insulin, 4 units (DRUG), Insulin, 20 units (DRUG), insulin, 4 units twice daily (DRUG), insulin, 20 units twice daily (DRUG), insulin, 4 units three times daily (DRUG).
Who is sponsoring clinical trial NCT05206877?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206877 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.